Mast Hücre Hastalıkları ve Anafilaksi

Müge TOYRANa, Hakan GÜVENİRb, Can Naci KOCABAŞc
aAnkara Şehir Hastanesi, Çocuk İmmünolojisi ve Alerji Hastalıkları Kliniği, Ankara, TÜRKİYE
bKocaeli Derince Eğitim ve Araştrma Hastanesi, Çocuk İmmünolojisi ve Alerji Hastalıkları Kliniği, Kocaeli, TÜRKİYE
cMuğla Sıtkı Koçman Üniversitesi Tıp Fakültesi, Çocuk İmmünolojisi ve Alerji Hastalıkları BD, Muğla, TÜRKİYE

Toyran M, Güvenir H, Kocabaş CN. Mast hücre hastalıkları ve anafilaksi. Akın C, Şekerel BE. editörler. Anafilaksi. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.18-24.

ÖZET
Mast hücreleri, deri, gastrointestinal sistem, solunum sistemi gibi birçok organ sisteminde bağ dokusunda bulunan ve dışarıdan gelen antijenlere karşı doğal bir bariyer oluşturan hücrelerdir. Mast hücrelerinden salınan mediyatörlere bağlı olarak birçok organ sistemine ait klinik belirtiler görülebilir. Mastositozis, mast hücrelerinin bir veya birden çok organda anormal birikimi sonucu görülen heterojen bir grup hastalığın adıdır. Mast hücresi aktivasyon sendromu ise mast hücrelerinden salınan mediyatörlere bağlı olarak tekrarlayıcı ve şiddetli sistemik klinik belirtilerin ortaya çıktığı bir grup hastalığa verilen isimdir. Mast hücresi ilişkili hastalıklar sıklıkla anafilaksi tablosunda karşımıza çıkmaktadır ve anafilaksi prevalansı bu grup hastalıklarda daha yüksektir. Bu hastalarda anafilaksiyi tetikleyici faktörlerden uzak durulmalı ve anafilaksi eylem planı hazırlanmalıdır. Gerekirse mast hücre duyarlılığını azaltan ilaçlar da kullanılabilir.

Anahtar Kelimeler: Anafilaksi; mast hücreleri

Referanslar

  1. Da silva Ez, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62(10):698-738. [Crossref]  [PubMed]  [PMC]
  2. Gilfillan AM, Austin SJ, Metcalfe DD. Mast Cell Biology: ıntroduction and Overview. Adv Exp Med Biol. 2011;716:2-12. [Crossref]  [PubMed]  [PMC]
  3. Gonzalez-de-Olano D, Alvarez-Twose ı. ınsights in Anaphylaxis and Clonal Mast Cell Disorders. Front ımmunol. 2017;8:792. [Crossref]  [PubMed]  [PMC]
  4. Coulson E, zhou S, Akin C. The Role of KıT Mutations in Anaphylaxis. Curr Allergy Asthma Rep. 2019;19(6):31. [Crossref]  [PubMed]
  5. González-de-Olano D, ı Álvarez-Twose ı. Mast Cells as Key Players in Allergy and ınflammation. J ınvestig Allergol Clin ımmunol. 2018; 28(6):365-78. [Crossref]  [PubMed]
  6. Kim HS, Kawakami Y, Kasakura K, K awakami T. Recent Advances in Mast Cell Activation and Regulation. F1000Res. 2020;9:196. [Crossref]  [PubMed]  [PMC]
  7. Weiler CR, Austen KF, Akin C, Barkoff MS, Bernstein JA, Bonadonna P, et al. AAAAı Mast Cell Disorders Committee Work Group Report: Mast Cell Activation Syndrome (MCAS) Diagnosis and Management. J Allergy Clin ımmunol. 2019;144(4):883- 96. [Crossref]  [PubMed]
  8. Valent P, Sperr WR, Schwartz lB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin ımmunol. 2004;114:3-11 [Crossref]  [PubMed]
  9. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017; 129(11):1420-7. [Crossref]  [PubMed]  [PMC]
  10. Broesby-Olsen S, Melody Carter M, Kjaer HF, Mortz CG, Møller MB, Kristensen TK, et al. Pediatric Expression of Mast Cell Activation Disorders. ımmunol Allergy Clin North Am. 2018;38(3):365-77. [Crossref]  [PubMed]
  11. Méni C, Bruneau J, Georgin-lavialle S, le Saché de Peufeilhoux l, Damaj G, Hadj-Rabia S, et al. Paediatric Mastocytosis: A Systematic Review of 1747 Cases. Br J Dermatol. 2015; 172(3):642-51. [Crossref]  [PubMed]
  12. Akin C. Mast cell activation disorders. J Allergy Clin ımmunol. 2017;140:349-55. [Crossref]  [PubMed]
  13. Arock M, Sotlar K, Gotlib J, Sperr WR, Hartmann K, Schwartz lB, et al. New Developments in the Field of Mastocytosis and Mast Cell Activation Syndromes: A Summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. leuk lymphoma. 2020;61(5):1075-83. [Crossref]  [PubMed]  [PMC]
  14. Valent P, Bonadonna P, Hartmann K, BroesbyOlsen S, Brockow K, Butterfield JH et al. Why the 20% + 2 Tryptase Formula ıs a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. ınt Arch Allergy ımmunol. 2019;180(1):44-51. [Crossref]  [PubMed]  [PMC]
  15. Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013;68(4): 417-24. [Crossref]  [PubMed]
  16. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin ımmunol Pract. 2019;7(4):1125-33. [Crossref]  [PubMed]  [PMC]
  17. Schuch A, Brockow K. Mastocytosis and Anaphylaxis. ımmunol Allergy Clin North Am. 2017;37(1):153-64. [Crossref]  [PubMed]
  18. González-de-Olano D, Matito A, AlvarezTwose ı. Mast Cell Activation Syndromes and Anaphylaxis: Multiple Diseases Part of the Same Spectrum. Ann Allergy Asthma ımmunol. 2020;124(2):143-5. [Crossref]  [PubMed]
  19. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226-32. [Crossref]  [PubMed]
  20. Matito A, Carter M. Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis? Curr Allergy Asthma Rep. 2015;15 (5):22. [Crossref]  [PubMed]
  21. Chapsa M, Roensch H, langner M, Beissert S, Bauer A. Predictors of severe anaphylaxis in Hymenoptera venom allergy: The importance of absence of urticaria and angioedema. Ann Allergy Asthma ımmunol. 2020 Mar 18. pii: S1081-1206(20)30151-4.
  22. Castells MC, Hornick Jl, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin ımmunol Pract. 2015;3(3):350-5. [Crossref]  [PubMed]
  23. Jendoubi F, Gaudenzio N, Gallini A, Negretto M, Paul C, Bulai livideanu C. Omalizumab in the treatment of adult patients with mastocytosis: A systematic review. Clin Exp Allergy. 2020 Feb 27. [Crossref]  [PubMed]
  24. Sokol KC, Ghazi A, Kelly BC, Grant JA. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin ımmunol Pract. 2014;2(3):266-70. [Crossref]  [PubMed]
  25. da Silva EN, Randall Kl. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin ımmunol Pract. 2013;1(6):687-8. [Crossref]  [PubMed]
  26. Alvarez-Twose ı, González de Olano D, Sánchez-Muñoz l, Matito A, Esteban-lópez Mı, Arantza Vega A, et al. Clinical, Biological, and Molecular Characteristics of Clonal Mast Cell Disorders Presenting With Systemic Mast Cell Activation Symptoms. J Allergy Clin ımmunol. 2010;125(6):1269-78. [Crossref]  [PubMed]
  27. Khokhar D, Akin C. Mast Cell Activation: When the Whole ıs Greater Than the Sum of ıts Parts. Med Clin North Am. 2020;104(1):177- 87. [Crossref]  [PubMed]
  28. Guyer AC, Saff RR, Conroy M, Blumenthal KG, Camargo CA, long AA, et al. Comprehensive allergy evaluation is useful in the subsequent care of patients with drug hypersensitivity reactions during anesthesia. J Allergy Clin ımmunol Pract. 2015;3(1):94- 100. [Crossref]  [PubMed]
  29. Carter MC, Metcalfe DD, Matito A, Escribano l, Butterfield JH, Schwartzet lB, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & ımmunology. J Allergy Clin ımmunol 2019; 143(3):880-93 [Crossref]  [PubMed]
  30. Matito A, Morgado JM, Sanchez-lopez P, Álvarez-Twose ı, Sánchez-Muñoz l, Orfao A, et al. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish network on mastocytosis (REMA) based on 726 anesthetic procedures. ınt Arch Allergy ımmunol. 2015;167(1):47-56 [Crossref]  [PubMed]
  31. Ishii K, Miyoshi H, Akiyama D, Makita T, Sumikawa K, Murata H, et al. Anesthetic management of patients with systemic mastocytosis. J Clin Anesth. 2018;50:61. [Crossref]  [PubMed]
  32. González de Olano D, de la Hoz Caballer B, Núñez lópez R, Sánchez Muñoz l, Agustin MC, Dieguez MC, et al. Prevalence of Allergy and Anaphylactic Symptoms in 210 Adult and Pediatric Patients With Mastocytosis in Spain: A Study of the Spanish Network on Mastocytosis (REMA). Clin Exp Allergy. 2007;37(10): 1547-55. [Crossref]  [PubMed]
  33. Commins SP, Satinover SM, Hosen J, Mozena J, Borish l, lewis BD, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with ıgE antibodies specific for galactose-alpha-1,3- galactose. J Allergy Clin ımmunol. 2009;123 (2):426-33 [Crossref]  [PubMed]  [PMC]
  34. Carter MC, Desai A, Komarow HD, Bai Y, Clayton ST, Clark AS, et al. A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. J Allergy Clin ımmunol. 2018;141(1): 180-8 [Crossref]  [PubMed]  [PMC]
  35. Gilreath JA, Tchertanov l, Deininger MW. Novel Approaches to Treating Advanced Systemic Mastocytosis. Clin Pharmacol. 2019;11: 77-92. [Crossref]  [PubMed]  [PMC]